# TABA: Tools for the site-specific labeling and immobilization of antibodies for immunoassays

> **NIH NIH R44** · ALPHATHERA, INC. · 2021 · $49,994

## Abstract

Summary: AlphaThera continues to scale commercialization of its site-specific antibody conjugation products and has encountered
welcoming signs of consumer interest across the US and the world, with sales in several countries and continued customer inquiries.
However, increasing expenses associated with scaling and commercialization have led us to explore additional sources of funds. The
TABA funds offered by the NIH/SBIR to support Phase I/Phase II grants are an ideal source of funding to enable AlphaThera to
continue on its fast-track towards scaled commercialization success. TABA funding will be allocated toward three major categories in
support of our commercialization: Multi-channel marketing; Strategic partner development and IP protection.

## Key facts

- **NIH application ID:** 10408659
- **Project number:** 3R44EB023750-03S3
- **Recipient organization:** ALPHATHERA, INC.
- **Principal Investigator:** Feifan Yu
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $49,994
- **Award type:** 3
- **Project period:** 2021-08-20 → 2022-08-09

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10408659

## Citation

> US National Institutes of Health, RePORTER application 10408659, TABA: Tools for the site-specific labeling and immobilization of antibodies for immunoassays (3R44EB023750-03S3). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/10408659. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*